Revised ISHAM-ABPA working group clinical practice guidelines for diagnosing, classifying and treating allergic bronchopulmonary aspergillosis/mycoses
-
Published:2024-02-29
Issue:4
Volume:63
Page:2400061
-
ISSN:0903-1936
-
Container-title:European Respiratory Journal
-
language:en
-
Short-container-title:Eur Respir J
Author:
Agarwal RiteshORCID, Sehgal Inderpaul SinghORCID, Muthu Valliappan, Denning David W.ORCID, Chakrabarti Arunaloke, Soundappan Kathirvel, Garg Mandeep, Rudramurthy Shivaprakash M., Dhooria SahajalORCID, Armstrong-James Darius, Asano Koichiro, Gangneux Jean-Pierre, Chotirmall Sanjay H.ORCID, Salzer Helmut J.F., Chalmers James D., Godet Cendrine, Joest Marcus, Page Iain, Nair Parameswaran, Arjun P., Dhar Raja, Jat Kana Ram, Joe Geethu, Krishnaswamy Uma Maheswari, Mathew Joseph L., Maturu Venkata Nagarjuna, Mohan Anant, Nath Alok, Patel Dharmesh, Savio Jayanthi, Saxena Puneet, Soman Rajeev, Thangakunam Balamugesh, Baxter Caroline G., Bongomin Felix, Calhoun William J., Cornely Oliver A.ORCID, Douglass Jo A., Kosmidis Chris, Meis Jacques F., Moss Richard, Pasqualotto Alessandro C., Seidel Danila, Sprute RosanneORCID, Prasad Kuruswamy Thurai, Aggarwal Ashutosh N.
Abstract
BackgroundThe International Society for Human and Animal Mycology (ISHAM) working group proposed recommendations for managing allergic bronchopulmonary aspergillosis (ABPA) a decade ago. There is a need to update these recommendations due to advances in diagnostics and therapeutics.MethodsAn international expert group was convened to develop guidelines for managing ABPA (caused byAspergillusspp.) and allergic bronchopulmonary mycosis (ABPM; caused by fungi other thanAspergillusspp.) in adults and children using a modified Delphi method (two online rounds and one in-person meeting). We defined consensus as ≥70% agreement or disagreement. The terms “recommend” and “suggest” are used when the consensus was ≥70% and <70%, respectively.ResultsWe recommend screening forA. fumigatussensitisation using fungus-specific IgE in all newly diagnosed asthmatic adults at tertiary care but only difficult-to-treat asthmatic children. We recommend diagnosing ABPA in those with predisposing conditions or compatible clinico-radiological presentation, with a mandatory demonstration of fungal sensitisation and serum total IgE ≥500 IU·mL−1and two of the following: fungal-specific IgG, peripheral blood eosinophilia or suggestive imaging. ABPM is considered in those with an ABPA-like presentation but normalA. fumigatus-IgE. Additionally, diagnosing ABPM requires repeated growth of the causative fungus from sputum. We do not routinely recommend treating asymptomatic ABPA patients. We recommend oral prednisolone or itraconazole monotherapy for treating acute ABPA (newly diagnosed or exacerbation), with prednisolone and itraconazole combination only for treating recurrent ABPA exacerbations. We have devised an objective multidimensional criterion to assess treatment response.ConclusionWe have framed consensus guidelines for diagnosing, classifying and treating ABPA/M for patient care and research.
Funder
International Society for Human and Animal Mycology, ISHAM
Publisher
European Respiratory Society (ERS)
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|